Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

MLA

Levy, Benjamin, et al. “Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.” Clinical Lung Cancer, vol. 20, no. 3, May 2019, pp. e407–12. EBSCOhost, https://doi.org/10.1016/j.cllc.2018.12.022.

APA

Levy, B., Paz-Ares, L., Bennouna, J., Felip, E., Abreu, D. R., Isla, D., Barlesi, F., Molinier, O., Madelaine, J., Audigier-Valette, C., Kim, S.-W., Kim, H. R., Ozguroglu, M., Erman, M., Badin, F. B., Mekhail, T. M., Scheff, R., Chisamore, M. J., Sadrolhefazi, B., & Riess, J. W. (2019). Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clinical Lung Cancer, 20(3), e407–e412. https://doi.org/10.1016/j.cllc.2018.12.022

Chicago

Levy, Benjamin, Luis Paz-Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Rodríguez Abreu, Dolores Isla, Fabrice Barlesi, et al. 2019. “Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.” Clinical Lung Cancer 20 (3): e407–12. doi:10.1016/j.cllc.2018.12.022.